Recent changes
DWORF Peptide SERCA Pump Activator Heart Failure Treatment
The USPTO published patent application US20260098067A1 by researchers at the University of Texas System covering the DWORF (Dwarf Open Reading Frame) peptide, a native SERCA pump activator for treating heart failure and disorders characterized by cytosolic calcium overload. The application claims compositions and methods using this positively inotropic and lusitropic therapeutic agent.
Recombinant Lubricin Patent - Schmidt and Jay Inventors
USPTO published patent application US20260098069A1 for recombinant isoforms of human-like lubricin (PRG4 glycoprotein) invented by Tannin A. Schmidt and Gregory D. Jay. The patent covers new lubricin isoforms with novel glycosylation patterns and methods for commercial-scale manufacturing using recombinant production methods.
SMAGP Fusion Molecules Modulate Leukocyte Activity
USPTO published patent application US20260098070A1 disclosing fusion molecules comprising a SMAGP extracellular domain designed to modulate leukocyte activity. The application covers polynucleotides, vectors, and host cells encoding these molecules along with methods of making and using them. Inventors include Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, and Nenad Grmusa, with filing date July 7, 2025.
GLP-1 Analog for Treatment of GLP-1 Related Diseases
USPTO published patent application US20260098071A1 for a novel human GLP-1 analog invented by Tao Sun. The disclosed analog demonstrates improved efficacy compared to natural GLP-1 sequence in treating obesity, type 2 diabetes mellitus, fatty liver, and mood disorders including anxiety and depression. The application was filed on December 4, 2024, under application number 18968327.
Methods of Stimulating Appetite Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
The USPTO published patent application US20260098072A1 by inventor Russell Potterfield on April 9, 2026, covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The application, filed April 18, 2025, relates to pharmaceutical compositions administered via parenteral routes such as subcutaneous injection for subjects requiring appetite stimulation and weight gain.
MITSUI CHEMICALS Carbamate Compound Patent Application
MITSUI CHEMICALS, INC. published a patent application (US20260098022A1) for a carbamate compound with specific molecular structure parameters. The application describes compounds where R1-R4 form monocyclic or polycyclic rings through various substituent linkages. CPC classifications include C07D 295/205, C07C 271/44, and C07C 275/32. Competitors developing similar chemical structures should review claims upon grant.
Rhodium Catalyst Method for Hydrogenation of Furfural to Bio-Fuel
The USPTO published patent application US20260098023A1 by King Fahd University of Petroleum and Minerals, covering a method for hydrogenating furfural to furfuryl ethyl ether bio-fuel using a rhodium nanoparticle catalyst (0.9-1.1 wt.% on alumina). The reaction achieves at least 99% conversion and 99% selectivity under ethanol and hydrogen atmosphere.
PARP1 Inhibitors and Uses Thereof
USPTO published patent application US20260098024A1 disclosing PARP1 inhibitor compounds and pharmaceutical compositions for cancer treatment. The application, filed on January 26, 2023 under application number 18833362, names six inventors including Robert L. Hoffman and Stephen W. Kaldor and covers compounds classified under C07D 401/12 and C07D 471/04.
Dimeric GYS1 Inhibitor Compounds for Metabolic Disorder Treatment
USPTO published patent application US20260098025A1 covering dimeric compounds of formula (I) as inhibitors of glycogen synthase 1 (GYS1), along with methods of preparing the compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. The application names nine inventors including David John Morgans Jr. and Christopher Joseph Sinz, with an original filing date of September 13, 2023.
M4 Receptor Activators Treat Alzheimer's Parkinson's Schizophrenia
The USPTO published patent application US20260098026A1 for M4 receptor activator/modulator compounds of Formula I, filed September 15, 2023. The compounds are intended for treating M4-mediated neurological disorders including Alzheimer's Disease, Parkinson's Disease, schizophrenia, pain, addiction, and sleep disorders. The application covers the compounds, N-oxides, salts, preparation processes, intermediates, and pharmaceutical compositions.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
691 changes in last 7 days
Latest high priority updates
140 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.